Native hMPV 3 Type B1 Lysate
Specification
Related Products
| Cat#: |
HUM-417 |
| Product Name: |
Native hMPV 3 Type B1 Lysate |
| Description: |
Human metapneumovirus 3 type B1 (Strain: Peru2-2002) lysate from LLC-mk2 cell line. Purified by sucrose density gradient ultracentrifugation and heat-inactivated, followed by verification with validated tissue culture infectivity assay. Suitable for the development of immunoassays, Western blotting, dot blotting and other protein-based assays. |
| Gene: |
hMPV 3 Type B1 Lysate |
| Species: |
HMPV |
| Synonyms: |
hMPV 3 Type B1 Lysate |
| Notes: |
This product is intended for research and manufacturing uses only. It is not a diagnostic device. The user assumes all responsibility for care, custody and control of the material, including its disposal, in accordance with all regulations. |
| Applications: |
Appropriate for the development of immunoassays, Western blotting, dot blotting and other protein-based assays. |
| Background: |
Human metapneumovirus (hMPV) is an enveloped, negative-sense, single-stranded RNA virus belonging to the genus Metapneumoviridae, of the family Pneumoviridae. hPMV is closely related to Respiratory Syncytial virus (RSV), which belongs to the genus Orthopneumovirus within the same family (Alfonso et al., 2016). Human metapneumovirus is globally widespread and spreads seasonally in temperate climates. Genomic analysis has shown that hMPV exists as two genotypes (A and B), which are further divided into the subgroups A1, A2, B1 and B2. Each subgroup has a distinct geographical distribution but can circulate separately or concurrently (Boivin et al., 2004). Transmission of HPMV from person-to-person predominantly occurs through contact with airborne droplets from an infected individual, produced by coughing or sneezing. It can also be spread through contact with contaminated hands or surfaces. Serosurveillance studies have shown that most children worldwide are infected with hMPV by the age of 5 (Shafagati et al., 2018). Rates of hospitalization of children for hMPV infection are highest in the first year of life but continue to occur throughout early childhood. Studies have tended to suggest that the peak age of hospitalization for hMPV is between 6 and 12 months of age, which is later than the peak age of hospitalization for RSV (2–3 months). |
For research use only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative BioMart.
